Panacea Biotec Tax Liability for AY 2016-17 Determined as Nil Post Rectification
Panacea Biotec received a rectified tax assessment order for AY 2016-17. The DCIT corrected errors, including double disallowances and omitted loss set-offs. The company's tax liability for the assessment year has been reduced to Nil, with no expected adverse financial impact.
The resolution of a significant tax demand of ₹10.23 Crore to Nil has a material positive financial impact, although it pertains to a past assessment year.
The rectification of the tax assessment order has resulted in the company's tax liability being reduced to Nil, which is a positive financial outcome.
Panacea Biotec Limited has received a rectified Assessment Order dated April 06, 2026, from the Deputy Commissioner of Income Tax (DCIT), New Delhi. This follows an earlier demand order dated March 01, 2026, which had disallowed certain expenditures, resulting in a total demand of approximately ₹10.23 Crore for Assessment Year 2016-17.
The company had filed a rectification application to correct apparent errors in the original order, specifically citing the double addition of disallowances and the omission of set-off for brought-forward losses. The DCIT has now addressed these errors in the rectified order.
Consequently, the Company's tax liability for AY 2016-17 has been revised and determined as Nil. Panacea Biotec Limited does not foresee any adverse financial, operational, or other impacts arising from this order.
What to do with a filing like this
Panacea Biotec Limited filed this with the NSE as a statutory disclosure, categorised under taxation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Panacea Biotec Limited. Read the original for the full detail.